Natera (NASDAQ:NTRA) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, BidAskClub reports.
A number of other equities research analysts have also weighed in on NTRA. Piper Jaffray Companies set a $45.00 price objective on Natera and gave the stock a “buy” rating in a research report on Friday, October 11th. Craig Hallum reissued a “buy” rating and set a $49.00 price target on shares of Natera in a research note on Thursday, December 19th. Canaccord Genuity restated a “buy” rating and set a $44.00 price target on shares of Natera in a report on Wednesday, October 16th. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating and set a $38.00 target price on the stock in a research report on Saturday, January 4th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Natera from $27.00 to $32.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Natera has an average rating of “Hold” and an average target price of $41.67.
NTRA traded up $2.39 during trading on Tuesday, hitting $37.23. 586,765 shares of the stock traded hands, compared to its average volume of 711,457. Natera has a twelve month low of $12.51 and a twelve month high of $40.92. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -17.32 and a beta of 1.35. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.35 and a quick ratio of 2.26. The business has a 50 day moving average price of $35.16 and a 200 day moving average price of $33.25.
Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.20. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The business had revenue of $77.90 million during the quarter, compared to the consensus estimate of $73.97 million. During the same period in the previous year, the business earned ($0.49) earnings per share. The company’s revenue was up 19.3% on a year-over-year basis. On average, equities research analysts predict that Natera will post -2.15 earnings per share for the current year.
In other news, COO Robert Alan Schueren sold 8,167 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $34.99, for a total value of $285,763.33. Following the transaction, the chief operating officer now owns 28,392 shares in the company, valued at approximately $993,436.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Jonathan Sheena sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $37.69, for a total transaction of $3,769,000.00. Following the completion of the transaction, the chief technology officer now owns 280,267 shares in the company, valued at approximately $10,563,263.23. The disclosure for this sale can be found here. Insiders sold 188,616 shares of company stock valued at $7,054,357 over the last 90 days. 9.29% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC lifted its holdings in Natera by 199.2% in the second quarter. Orbimed Advisors LLC now owns 3,224,328 shares of the medical research company’s stock valued at $88,927,000 after buying an additional 2,146,742 shares during the period. BlackRock Inc. lifted its stake in shares of Natera by 74.4% in the 2nd quarter. BlackRock Inc. now owns 4,842,318 shares of the medical research company’s stock valued at $133,552,000 after purchasing an additional 2,065,977 shares during the period. Millennium Management LLC lifted its stake in shares of Natera by 1,562.8% in the 3rd quarter. Millennium Management LLC now owns 2,191,733 shares of the medical research company’s stock valued at $71,888,000 after purchasing an additional 2,059,920 shares during the period. Invesco Ltd. lifted its stake in shares of Natera by 4,307.7% in the 2nd quarter. Invesco Ltd. now owns 2,041,857 shares of the medical research company’s stock valued at $56,314,000 after purchasing an additional 1,995,532 shares during the period. Finally, Nuveen Asset Management LLC acquired a new position in shares of Natera in the 2nd quarter valued at about $24,302,000. Institutional investors own 84.93% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.